SC Therapies

SCS mouse NS cells currently being used in pre-clinical trials

SC Therapies’ will develop safe and effective cell-based therapies for current major unmet medical needs. SCS is engaged in new pre-clinical programmes to evaluate the repair capacity of the Company’s stem cell lines, particularly its proprietary NS cell technology in models of acute & age dependent, chronic nervous system dysfunction. Concurrently, SCS KK, the Japanese associate company, is executing plans for pre-clinical cell therapy research into Duchenne Muscular Dystrophy (DMD).

In initial phases SC Therapies will focus on the development of treatments for central nervous system (CNS) disorders, including acute spinal cord injury, Parkinson’s disease, epilepsy and for key orphan indications. Subsequent focus will be on other major unmet medical conditions in which there is a strong case for SCS’ stem cell types feasibly leading to effective restoration of tissue function.

Improvements to its existing technology and further innovation for additional technology required to support SCS’ cell therapy programme will stem from key, collaborative consortia, such as the EU FP6 research programmes. Additional technology required to successfully deliver effective therapies in the clinic will be sought from in-licensing or technology acquisitions.

SCS KK has licensed the rights to the development of protocols and therapeutic products made from human multipotent adipose derived stem (hMADS) cells for transplantation in humans. SCS-KK has also leased a GMP (Good Manufacturing Practice) cell processing facility in Kobe, Japan, specifically for the purpose of commencing production and supply of clinical grade cells, subsequent to successful pre-clinical trials for a number of indications including DMD.

SCS plc and SCS-KK are collaborating with the Universty of Nice on further pre-clinical research for the development of treatments for muscle repair. In a territory defined arrangement SCS plc will benefit from future commercialization of a successful treatment for muscular dystrophy.

For further details of our progress in pre-clinical programmes, information on SCS’ novel approach to modelling human disease or enquiries relating to technology accessibility please contact:

Tim Allsopp
Chief Scientific Officer
tim.allsopp@stemcellsciences.com
+44 1223 499161